Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

By WebmasterJanuary 17, 2018November 1st, 2024No Comments

Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

Previous PostPillo Health and Orbita Partner to Deliver Engaging Voice-first Experiences via a First-of-its-kind Digital Care Management Platform for Home
Next PostBioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018